Delayed administration of high dose human immunoglobulin G enhances recovery after traumatic cervical spinal cord injury by modulation of neuroinflammation and protection of the blood spinal cord barrier

NEUROBIOLOGY OF DISEASE

卷:148

Article

Chio, Jonathon Chon Teng^1,2,4  Wang, Jian^1,4  Surendran, Vithushan^1,4  Li, Lijun^1,4  Zavvarian, Mohammad-Masoud^1,2,4  Pieczonka, Katarzyna^1,2,4  Fehlings, Michael G.^1,2,3 

[1] Univ Hlth Network, Krembil Res Inst, Div Translat & Expt Neurosci, Toronto, ON, Canada

[2] Univ Toronto, Inst Med Sci, Toronto, ON, Canada

[3] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada

[4] Krembil Discovery Tower, 60 Leonard Ave,7KD-430, Toronto, ON M5T 2S8, Canada

关键词: Rat;    Spinal cord injury;    Human immunoglobulin G;    High dose;    Neuroinflammation;    Immunomodulation;    Time window of administration;    Blood-spinal cord-barrier;    Neutrophils;    Tissue preservation;    Neuroprotection;    Functional recovery;    Sensory recovery;   

DOI  :  10.1016/j.nbd.2020.105187

来源: Elsevier

【 摘 要 】

Background/introduction: The neuroinflammatory response plays a major role in the secondary injury cascade after traumatic spinal cord injury (SCI). To date, systemic anti-inflammatory medications such as methylprednisolone sodium succinate (MP55) have shown promise in SCI. However, systemic immunosuppression can have detrimental side effects. Therefore, immunomodulatory approaches including the use of human immunoglobulin G (hIgG) could represent an attractive alternative. While emerging preclinical data suggests that hIgG is neuroprotective after SCI, the optimal time window of administration and the mechanism of action remain incompletely understood. These knowledge gaps were the focus of this research study. Methods: Female adult Wistar rats received a clip compression-contusion SCI at the C7/T1 level of the spinal cord. Injured rats were randomized, in a blinded manner, to receive a single intravenous bolus of hIgG (2 g/kg) or control buffer at 15 minutes (min), 1 hour (h) or 4 h post-SCI. At 24 h and 8 weeks post-SCI, molecular, histological and neurobehavioral analyses were undertaken. Results: At all 3 administration time points, hIgG (2 g/kg) resulted in significantly better short-term and long-term outcomes as compared to control buffer. No significant differences were observed when comparing outcomes between the different time points of administration. At 24 h post-injury, hIgG (2 g/kg) administration enhanced the integrity of the blood spinal cord barrier (BSCB) by increasing expression of tight junction proteins and reducing inflammatory enzyme expression. Improvements in BSCB integrity were associated with reduced immune cell infiltration, lower amounts of albumin and Evans Blue in the injured spinal cord and greater expression of anti-inflammatory cytokines. Furthermore, hIgG (2 g/kg) increased expression of neutrophil chemoattractants in the spleen and sera. After hIgG (2 g/kg) treatment, there were more neutrophils in the spleen and fewer neutrophils in the blood. hIgG also co-localized with endothelial cell ligands that mediate neutrophil extravasation into the injured spinal cord. Importantly, short-term effects of delayed hIgG (2 g/kg) administration were associated with enhanced tissue and neuron preservation, as well as neurobehavioral and sensory recovery at 8 weeks post-SCI. Discussion and conclusion: hIgG (2 g/kg) shows promise as a therapeutic approach for SCI. The anti-inflammatory effects mediated by hIgG (2 g/kg) in the injured spinal cord might be explained in twofold. First, hIgG might antagonize neutrophil infiltration into the spinal cord by co-localizing with endothelial cell ligands that mediate various steps in neutrophil extravasation. Second, hIgG could traffic neutrophils towards the spleen by increasing expression of neutrophil chemoattractants in the spleen and sera. Overall, we demonstrate that delayed administration of hIgG (2 g/kg) at 1 and 4-h post-injury enhances short-term and long-term benefits after SCI by modulating local and systemic neuroinflammatory cascades.